A B2B certification and licensing program that provides private psychiatric practices with a manualized clinical protocol for psychedelic-assisted therapy. The service includes training, adherence tracking tools, and standardized session roadmaps for integrating psilocybin or MDMA into clinical care.
The PESTEL analysis reveals a high-potential opportunity driven by strong clinical evidence and shifting social attitudes, but one that is heavily constrained by a fragmented and volatile legal landscape. The business model cleverly pivots from substance distribution to methodology licensing, mitigating direct regulatory risk while remaining dependent on the legal status of the substances it supports.
Political2
Economic3
Social2
Technological2
Environmental1
Legal3
The viability of the protocol is entirely dependent on the shifting legal and regulatory landscape regarding controlled substances. · Generated 2026-09-22 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated